The investigation of efficacy and safety about the clinical pathway for congestive heart failure specified immediate use of tolvaptan after admission in super-elderly patients.
Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy